RxDoctor Payments Data

Edward Dimitry, MD

Pulmonary Disease · Summit, NJNPI 1275534323

Payments from drug & device makers

$711in general payments, 2019–2025

Across 53 payments — averaging $13.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$359
  • Genentech USA, Inc.$68
  • Amgen$66
  • Regeneron Healthcare Solutions, Inc.$47
  • Jazz Pharmaceuticals Inc.$44
  • AstraZeneca$28
  • plus $97 from 6 others

What the payments were for

  • Food & beverage$67795%
  • Education$345%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$711 in reported general payments places this provider in the 30th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$270,953
Medicare patients
930
Services billed
3,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter544$467,079
OfevNintedanib Esylate28$363,356
Incruse ElliptaUmeclidinium Bromide435$178,453
Breo ElliptaFluticasone/Vilanterol301$178,437
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr237$142,507
Spiriva HandihalerTiotropium Bromide89$83,331
Spiriva RespimatTiotropium Bromide96$73,254
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$60,550
Dupixent SyringeDupilumab13$45,185
Pirfenidone35$36,082
Advair HfaFluticasone Propion/Salmeterol97$34,893
Fluticasone-SalmeterolFluticasone Propion/Salmeterol233$34,701
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$24,320
EliquisApixaban30$24,021
Albuterol Sulfate HfaAlbuterol Sulfate511$19,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$359$984,5051,581 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$14$460,930157 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$28$92,872138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Summit

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →